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ABSTRACT 
Objective: Chitosan nanoparticles (ChNP’s) have been widely studied for drug and gene delivery. In this study, we prepared ChNP’s for co-delivery 
of doxorubicin (DOX) and siRNA for cancer treatment.  
Methods: The ionic gelation method was used to develop ChNP’s. The positively charged DOX and negatively charged siRNA encapsulated into 
ChNP’s. The particle size and zeta potential of the developed ChNP’s were studied by particle size analyzer and morphology was examined by TEM. 
Encapsulation of DOX in ChNP’s was confirmed by FTIR spectroscopy. The encapsulation efficiency and in vitro release of DOX were studied by UV-
Vis spectrophotometry. The siRNA loading into ChNP’s was confirmed by gel retardation assay.  
Results: The developed ChNP’s showed particle size ranged from 127±6.5 to 215±8.5 nm with zeta potential ranged from 16.5±0.3 to 25.8±0.3. 
Transmission Electron Micrograph showed DOX and siRNA encapsulated ChNP’s are polydisperse and spherical in nature. FTIR study confirmed the 
binding of DOX with ChNP’s with absorption peaks at 1016 cm-1, 1316 cm-1, 1412 cm-1, 1645 cm-1 and 3370 cm-1. The TPP:Ch ratio 0.1:0.5 showed 
the highest encapsulation efficiency 69±3.24%, with initial burst release and then sustained or slow release of DOX. Agarose gel retardation study 
confirmed the encapsulation of siRNA in ChNP’s by retarded migration of siRNA-ChNP’s in comparison with naked siRNA.  
Conclusion: The developed ChNP’s successfully encapsulated the DOX and siRNA and showed the sustain release of DOX. In conclusion, our study 
shown that ChNP’s is having a potential of co-loading of DOX-siRNA as an efficient drug delivery system for the treatment of various cancers such as 
colorectal cancer, breast cancer etc. 
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INTRODUCTION 
Now a days, cancer is one of the main causes of death worldwide. 
Conventional therapies such as radiotherapy, surgery, 
chemotherapy and a combination of them are used to treat cancer 
[1]. Chemotherapy is one of the most commonly used treatment in 
which chemotherapeutics are used for treatment of cancer. Some 
most common chemotherapeutics such as 5-FU, paclitaxel, DOX are 
capable for suppression of tumor growth [2, 3].  
DOX is an anthraquinone, hydrophilic anticancer drug that binds to 
topoisomerase, which induces apoptosis in different malignant cancer. 
However, problems related to acquired resistance and their acute 
cardiotoxicity, low penetration and limited distribution in solid tumor 
[4, 5]. Due to this side effects use of free DOX in the biomedical field is 
still limited. An alternative approach is to reduce side effects 
encapsulate DOX within a positively charged nanocarrier. Nanocarrier 
based drug delivery systems offer several advantages, including the 
greater surface area of nanoparticles, due to reduced size, sustained 
drug release rate, improvement in biodistribution, and reduction in 
side effects [6, 7]. Recently, nanocarriers are used for drug delivery are 
polymeric nanoparticles, micelles, dendrimers etc. Polymeric 
nanoparticles are most studied carriers in drug delivery, which 
exhibits pH-responsive, drug retaining ability during circulation and 
releasing it at the tumor site. A major problem with chemotherapeutic 
drugs is the gradually acquired multidrug resistance (MDR) due to the 
overexpression of active drug efflux pumps, which reduces the 
therapeutic efficacy. Even the use of siRNAs that target particular 
genes has been shown to reduce resistance problems. However, 
delivering siRNA to tumor cells is a major challenge because serum 
nucleases degrade siRNA and are immediately cleared by the 
reticuloendothelial system (RES) [8, 9]. The Discovery of RNA 
interference (RNAi)-based gene silencing has drawn much attention to 
cancer therapy due to its unique properties to silence a broad range of 
genetic targets. RNA interference (RNAi) is a cellular mechanism for 
gene suppression induced by siRNA in which 21-23 base pairs 
sequence of siRNA complementary to its target mRNA, which acts as a 
post-transcriptional regulator [10]. For clinical success, there is a 
major challenge associated with siRNA delivery at target site and 
cellular uptake. Some physiological and biological barriers are 
preventing their delivery at target site. But still, most practical 
applications need a carrier to transport the siRNA via systemic 
application to the target site [11-13]. 
Co-delivery of siRNA and encapsulated chemotherapeutic drugs is a 
promising approach to improve therapeutic efficacy. Various studies 
have shown that nanocarrier-based co-delivery of drugs with siRNA 
against the MDR genes suppressed P-glycoprotein (P-gp) expression 
which increases the retention of encapsulated drugs [8, 14].  
Ch is a naturally occurring linear cationic polymer prepared through 
N-deacetylation of chitin isolated from seaweeds. Recently, it has 
increasing attention in pharmaceutical and biomedical applications 
because of its biocompatibility, biodegradability, non-toxicity, 
cationic properties and bioadhesive characteristics. Thus, ChNP’s are 
of great significance as drug delivery systems for cancer therapy [5, 
6]. The ChNP’s can be formulated through various techniques, such 
as coacervation, co-precipitation, solvent evaporation, ionic gelation, 
and microemulsion. In ionic gelation method, several cross-linking 
agents such as sodium tripolyphosphate and glutaraldehyde are 
used, which provide an efficient network to entrap the drug 
molecules into the nanoparticles [7, 15]. Here, we developed DOX 
and siRNA encapsulated ChNP’s in order to create an efficient drug 
delivery system. Physicochemical properties of the DOX and siRNA 
encapsulated ChNP’s were studied, such as particle size, surface 
charge, percentage encapsulation efficiency and in vitro-drug 
release, gel retardation assay. 
MATERIALS AND METHODS 
Materials 
Low mol. wt. Ch (Mol. Wt. 50,000–190, 000 Da, Deacetylation Degree 
75-85%), sodium tripolyphosphate (TPP) was purchased from 
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Sigma-Aldrich (Mumbai, India), Acetic acid, Tween 80, 1 M NaOH, 
HCl, Agarose gel electrophoresis kit was purchased from Himedia 
Laboratories Pvt. Ltd, Mumbai, India. DOX Hydrochloride was 
received as a gift sample from Sun Pharma Advance Research co Ltd, 
India. The siRNA was purchased from Santacruze Biotech, India. All 
other chemicals used were of analytical grade. Double distilled water 
(DDW) and RNase free water used throughout the study wherever 
needed. 
Preparation of ChNP’s 
ChNP’s were prepared via ionic gelation method established by 
Calvo et al. [16] Ch solutions (0.3%, 0.4%, 0.5%, 0.6% w/v, pH-5.5) 
were prepared by dissolving Ch in 1% v/v glacial acetic acid. TPP 
solution (0.1% w/v) was prepared by dissolving TPP in deionized 
water. ChNP’s were prepared by adding TPP solution dropwise into 
Ch solutions at room temperature with constant magnetic stirring 
for 1hr. Centrifugation was performed at 20,000 rpm at 10 °C for 30 
min to collect nanoparticles. The supernatant was discarded and 
pellets of nanoparticles re-suspended in filtered deionized water.  
Preparation of DOX encapsulated ChNP’s 
After optimization of Ch and TPP ratio 0.5:0.1 were selected for DOX 
encapsulation. To prepare DOX encapsulated ChNP’s, DOX solution 
(Ch:DOX-10:1) were added into aqueous solution of TPP. Prepared 
TPP-DOX solution dropwise added into Ch solution under constant 
magnetic stirring for 1hr. at R. T.  
Preparation of DOX and siRNA encapsulated ChNP’s 
For preparation of DOX and siRNA encapsulated ChNP’s, DOX (Ch: 
DOX–10:1) and 5μl of siRNAs (20 μg/μl) was added to 1.5 ml 
aqueous solution of TPP (0.1% w/v), then this solution was 
dropwise added into Ch (0.5%, pH–5.5) solution under magnetic 
stirring at R. T. Then particles were incubated at room temperature 
for another 30 min before further analysis. All solutions were made 
in RNase-free distilled water and autoclaved before use. To prevent 
photodegradation of DOX, glassware’s was used either amber color 
or covered with aluminum foil. 
Characterization 
Physicochemical characterization 
Nanoparticles diameter, polydispersity index and zeta potential 
were determined by Malvern Zetasizer Ver. 7.12 (Malvern 
Instruments Ltd, UK). The aqueous dispersions of the nanoparticles 
were measured at 25 °C with a scattering angle of 90 °. 
Morphology of nanoparticles 
The ChNP’s morphology was examined by transmission electron 
microscopy at 200 kv (JEOL Model JEM-2100). 
Fourier transform infrared spectroscopy (FTIR) 
Fourier transform infrared (FTIR) spectra were analyzed using an 
Alpha Bruker, Germany in the range 4000-400 cm-1. The DOX, 
ChNP’s, DOX-ChNP’s samples were mixed with KBr and form a thin 
pellet to investigate the functional group.  
Encapsulation efficiency of DOX 
The encapsulation efficiency of DOX into ChNP’s was measured 
using a UV-vis spectrophotometer at 480 nm. The free DOX in 
supernatant recovered from centrifugation (20,000 at 10 °C for 30 
min) were quantified by measuring its absorbance at 480 nm 
wavelength with a dual beam Agilent Technologies Cary 60 UV-Vis 
spectrophotometer. 
 
Where, C (sample) is the concentration of DOX added and C 
(supernatant) is the concentration of DOX in the supernatant (6). 
In vitro release study of DOX 
4 ml of DOX loaded ChNP’s were dispersed in a freshly prepared 
phosphate-buffered saline (PBS; pH = 7.4) as a release medium in a 
dialysis membrane sac (molecular weight cut-off 12 kDa). The 
ChNP’s containing sac dialysis in 50 ml PBS (pH-7.4) as released 
media. The beaker was placed in a shaking incubator at 37ᵒC under 
mild agitation. For each sample, 5 ml of the release medium was 
withdrawn at prearranged time intervals and replaced with the 
same amount of medium every time. The amount of released DOX in 
the medium was assessed at absorbance (λ = 480 nm) by UV-Vis 
spectrophotometry. The medium which was collected from plain 
NPs (without DOX) were used as the negative control. The 
percentage of cumulative DOX release was calculated according to 
the standard curve [10]. 
Confirmation of siRNA encapsulation in ChNP’s by Agarose gel 
retardation assay 
The binding of siRNA into ChNP’s was confirmed by agarose gel 
retardation assay. Naked siRNA and prepared ChNP’s, ChNP’s-
siRNA samples were taken for loading. Before loading into the 
agarose gel, all samples were incubated and shaken gently at 37 °C 
for 30 min; after that adding 5 μl of loading buffer into all samples. 
The samples were electrophoresed in 1% (w/v) agarose gel 
containing ethidium bromide (2 mg/ml) at a constant voltage of 
120 V for 20 min. The results was observed under the UV 
transilluminator [17].  
RESULTS AND DISCUSSION 
ChNP’s were prepared according to the ionic gelation method 
using negatively charged polyanion crosslinker TPP, which binds 
reversibly to positively charged Ch through electrostatic 
interaction at room temperature. This is an organic solvent-free 
method with a better ability to encapsulating hydrophilic drug 
DOX and siRNA [5, 15].  
Physicochemical characterization 
The DOX and siRNA encapsulated ChNP’s were optimized on the 
basis of size distribution, surface charge, polydispersity index and 
encapsulation efficiency (table 1). The results revealed that Ch:TPP 
ratio 0.1:0.5 was found optimum on the basis of maximum 
percentage DOX encapsulation efficiency (69±3.24 %) with optimum 
size and distribution (192±8.1 and 0.62±0.05). 
Morphology of nanoparticles 
The morphology of ChNP’s was confirmed by TEM in which ChNP’s 
were seen to be spherical with solid dense structure. The 
nanoparticles were appeared to be considerably smaller than the 
average particle size observed with the particle size analyzer. 
  
Table 1: Optimization of DOX and siRNA encapsulated ChNP’s 
 TPP: Ch (ratio) Particle size (nm)  Zeta potential (mV)  PDI  Encapsulation efficiency 
0.1:0.3 127±6.5 16.5±0.3 0.86±0.03 39±2.14 % 
0.1:0.4  158±6.7 22.4±0.5 0.63±0.05 52±2.84 % 
0.1:0.5 192±8.1 24.6±0.3 0.62±0.05 69±3.24 % 
0.1:0.6 215±8.5 25.8±0.3 0.96±0.05 65±2.78 % 
Values represent mean±SD (n = 3)  
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FTIR spectroscopy is an important tool used to determine the 
functional groups in a molecule. In fig. 2 shown FTIR spectra of 
ChNP’s, DOX, ChNP’s-DOX. In ChNP’s wider peak was observed at 
3302 cm-1 due to the development of hydrogen bonding and 
shoulder peak at 1624 cm-1. In DOX-loaded ChNP’s the 
absorption bands appeared at 1016 cm-1 and 1645 cm-1 are 
related to the DOX [18]. 
 
Fig. 2: FTIR spectra of a) ChNP’s b) DOX c) DOX-ChNP’s 
 
Encapsulation efficiency and in vitro drug release  
The DOX (DOX:Ch–1:10) encapsulated in all formulations of TPP: Ch. 
Encapsulation efficiencies shown in table 1. TPP:Ch (0.1:0.5) showed 
higher encapsulation efficiency (69±3.24 %). In vitro release of DOX 
were performed in phosphate buffer saline at pH–7.4 physiological pH of 
body fluids. The average cumulative release of DOX from nanoparticles 
at the prefixed time interval is shown in fig. 2. The release profile was 
biphasic. It was apparent that in vitro DOX release showed initial burst 
release and slower release of DOX in the second phase. After, 48 h it was 
shown 86.6±4.78 % of DOX released from ChNP’s. 
 
 
Fig. 3: In vitro release profile of DOX 
 
 
Fig. 4: Agarose gel retardation assay 
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Agarose gel retardation assay 
The agarose gel retardation assay was used to confirm the loading of 
siRNA into ChNP’s. The Naked siRNA and prepared formulations such as 
ChNP’s and siRNA-ChNP’s were loaded on agarose gel as shown in fig. 4. 
The results showed that naked siRNA moved with their electrophoretic 
mobility and shown as dark band on agarose gel. The ChNP’s did not 
showed any migration and fluorescence. Whereas, siRNA-ChNP’s 
showed retarded movement. The results clearly revealed that the siRNA 
was successfully loaded in ChNP’s. 
CONCLUSION 
The ChNP’s, DOX-ChNP’s, DOX-siRNA-ChNP’s were successfully 
prepared by ionic gelation method. The TPP:Ch ratio 1:5 was found 
optimum for ChNP’s formulation on the basis of optimum particle size 
and highest encapsulation efficiency (69±3.24 %). In vitro release of 
DOX were showed initial burst release and prolong sustained-release 
i.e. 86.6±4.78 % at the end of 48 h. The loading of siRNA in ChNP’s was 
confirmed by agarose gel electrophoresis retardation assay. The 
developed DOX-siRNA-ChNP’s having wide scope for further research 
in vitro and in vivo to treat various types of cancer such as colorectal 
cancer, breast cancer and other solid tumors. 
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